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school 4 years after implantation. This prospective economic analysis adopted 
the health care payer’s perspective and took into account direct medical,  
direct non-medical and indirect costs RESULTS: Two hundred and three 
implanted children were included in the study and followed during four years. 
The rate of school children implanted later (i.e. after 2 years) goes from 71,4% to 
95,3% four year after implantation and goes from 28,6% to 87,5% for children 
implanted earlier (i.e. before 2 years). If children are implanted earlier (i.e. < 2 
years), they are more likely to integrate ordinary classroom four years after 
implantation (69.0%) than if children were implanted later (46,9%). The mean 
total costs over one year period were €34,703 (+/- 5,231). The preoperative, 
implantation and one year follow-up mean costs were €1,304 (+/- 1,014), €24,285 
(+/- 1,150) and €9,115 (+/-4,694) respectively. Ambulatory care was the costs 
driver in preoperative and one year follow up costs (42,0% and 66,6% 
respectively), while in implantation costs the driver was implant cost (90,0%). 
The cost of the next three year follow-up is being processed CONCLUSIONS: CI is 




USE OF BIOLOGIC AGENTS IN THE TREATMENT OF PSORIASIS: AN ANALYSIS 
OF THE QUEBEC PROVINCIAL DRUG REIMBURSEMENT PROGRAM  
DATABASE  
Lachaine J1, Beauchemin C1, Desjardins O2 
1University of Montreal, Montreal, QC, Canada, 2Abbvie, St-Laurent, QC, Canada  
OBJECTIVES: The purpose of this study was to describe the use of biologics in the 
treatment of psoriasis, in a real life Canadian setting. METHODS: A retrospective 
study of the Quebec provincial drug reimbursement program (RAMQ) was 
conducted using a random sample of patients who had received at least one 
diagnosis of psoriasis (ICD-9: 6961/6968/6969) and had used at least one biologic 
in the period from January 1, 2001 to August 31, 2011. Agents included in the 
study were adalimumab, etanercept, infliximab, abatacept, anakinra, efalizumab, 
golimumab, rituximab, tocilizumab and ustekinumab. The use of biologics was 
analyzed in terms of patient characteristics, treatment patterns and health care 
resource utilization. RESULTS: A total of 1382 patients who used at least one 
biologic were included in the study. The average age was 45,8 years (SD=15,0) 
and the proportion of men was slightly higher (53,5%). Most patients had other 
concomitant inflammatory diseases (80,8%), such as rheumatoid arthritis (48.6%), 
psoriatic arthritis (44.9%), and Crohn’s disease (15.0%). During the course of the 
study period, most patients used only one biologic (80.3%). Out of the 34,320 
scripts for a biologic, 16,421 were for etanercept (47.9%), 8,868 for adalimumab 
(25.8%) and 7174 for infliximab (20.9%). Average annual cost for biologics in 
psoriasis was $19,026 and was slightly higher in the first year of treatment. Costs 
per patient of health care resource utilization in the year following the initiation 
of a biologic were $CAD486 lower than during the one year period preceding the 
biologic initiation; 45% of this reduction was associated with outpatient visits 
and 23% with hospitalizations. CONCLUSIONS: Psoriasis is associated with many 
other inflammatory conditions. Biologics use for the treatment of psoriasis has 
significantly increased over time. Although this is associated with higher 
medication costs, the initiation of a biologic is associated with a reduction of 
other medical costs.  
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DIALYSIS FACILITY-LEVEL ANALYSIS OF THE ECONOMIC IMPACT OF PRURITUS 
AMONG END-STAGE RENAL DISEASE PATIENTS RECEIVING HEMODIALYSIS 
THERAPY  
Ramakrishnan K1, Graybill CA1, Massey K2, Sood V2, Sibbel SP1 
1DaVita Clinical Research, Minneapolis, MN, USA, 2Mitsubishi Tanabe Pharma America, Inc., 
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OBJECTIVES: Itchy and dry skin, symptoms of pruritus, are commonly reported 
by patients with end-stage renal disease (ESRD) and may impact health 
outcomes. However, the economic burden to dialysis facilities is poorly 
understood. This retrospective cohort study measured dialysis-related costs in 
patients reporting itchiness/dryness at a large dialysis organization (LDO). 
METHODS: Adult patients (≥ 18 years old) were identified in the LDO database if 
they responded to the Kidney Disease Quality of Life (KDQOL) survey 
administered between December 1, 2008 and June 30, 2012, which included 
questions about itchy/dry skin. Medicare patients were included if they 
answered a survey ≥ 3 months after dialysis initiation. Costs of medications, 
laboratories, and missed sessions were measured over a 6-month follow-up 
period. Patients were censored for death, transplant, change in treatment 
modality, discontinued treatment, or loss of observation. Mean utilization for 
medication and laboratory costs was determined by unit prices published in RED 
BOOK and physician fee and coding guide. Costs of missed sessions were derived 
by the standard 2012 Medicare composite reimbursement rate for in-center 
dialysis. Cost differences were determined by covariate adjusted generalized 
linear mixed models. RESULTS: Over the 6-month period, in unadjusted models 
(n = 38,815) increasing trends in total costs were observed with increasing 
severity of itchiness ($507, $803, $1,520, and $2,238) and dryness ($542, $840 
$1,610, and $2,729) compared to no itchiness/dryness. The adjusted model 
demonstrated similar trends, yet attenuated differences. A subgroup analysis 
comparing combined severe itchiness and dryness versus neither itchiness nor 
dryness showed a mean estimate of $2348 increased costs. All results were 
statistically significant (p < 0.0001). Drivers of overall dialysis costs were 
increased utilization of erythropoiesis-stimulating agents and missed sessions. 
CONCLUSIONS: ESRD patients with pruritus symptoms impose higher costs to 
dialysis facilities. Pruritus symptom relief may be an important target for 
therapeutic intervention.  
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COST-EFFECTIVENESS OF INTRAVITREAL AFLIBERCEPT INJECTION (IAI) IN 
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OBJECTIVES: Anti-VEGF therapy with ranibizumab (RBZ) dosed monthly improves 
visual acuity over time in patients with neovascular (“wet”) age-related macular 
degeneration (wAMD). In two identical phase 3 trials, IAI dosed every 2 months, 
following 3 initial monthly doses demonstrated clinically equivalent efficacy and a 
similar safety profile to RBZ0.5mg dosed monthly (RBZQ4). We assessed U.S. cost 
effectiveness of IAI 2Q8 compared with RBZ Q4 in treating wAMD. METHODS: A 
Markov model was developed to characterize treatment with IAI 2Q8 and RBZ Q4 
over two years. Patients move among health states based on visual acuity in the 
better-seeing eye. The model assumed patients discontinue treatment when vision 
drops below 20/400; ten percent were assumed to be treated in both eyes. The 
model calculated direct medical costs (drug, administration, monitoring, vision 
impairment and adverse events) and quality adjusted life-years (QALYs). Model 
parameters were estimated from clinical trial data, published literature, or expert 
opinion. Cost-effectiveness was reported through incremental cost-effectiveness 
ratios (ICERs) for a 2-year horizon. Costs and outcomes were discounted 3% per 
year. Deterministic and probabilistic sensitivity analyses were performed. RESULTS: 
Treatment with IAI 2Q8 cost $30,700 over two years, compared with $54,300 for RBZ 
Q4. Treatment cost was the largest cost component, comprising 78% and 85% of 
total costs of the IAI and RBZ regimens, respectively. Both regimens resulted in 
similar QALY gains (1.124 for IAI, 1.125 for RBZ). Compared with IAI, RBZ cost nearly 
$26 million per QALY gained. The model was most sensitive to unit drug cost and 
utility weights. IAI was dominant in 41% of PSA iterations. CONCLUSIONS: In 
treating wAMD, IAI 2mg dosed every 2 months, following 3 initial monthly doses is 
less expensive than monthly RBZ. Both demonstrate similar efficacy. Of the two, IAI 
is the cost-effective alternative at conventional willingness to pay thresholds.  
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OBJECTIVES: To determine the comparative cost-effectiveness of three 
commercially available cellular engineered skin substitutes used in the 
treatment of venous leg ulcers (VLU). METHODS: A Markov simulation model 
was developed to compare the one year direct costs and outcomes of a porcine 
small intestinal submucosa (SIS) wound matrix to fibroblast-derived (FSS) and 
fibroblast/keratinocyte-derived (FKSS) cellular and/or tissue-derived products 
(CTDP) used in the treatment of chronic VLUs. The model used three health 
states: a chronic ulcer, a healed ulcer and death. To predict clinical and 
economic outcomes a systematic literature search was conducted to identify 1) 
comparative chronic VLU clinical trials that reported healing/recurrence 
outcomes for the three skin substitutes, and 2) economic studies reporting VLU 
treatments and resource utilization. The effectiveness of the products was 
assumed equal to that reported in four clinical trials identified in the literature. 
Ulcer-free weeks were used as the measure of clinical effectiveness. Direct costs 
of treatment were derived from Medicare-allowable costs and economic studies 
identified in the literature which included costs associated with hospitalization, 
home health care, ambulatory clinic visits, CTDP products, drugs, compression 
stockings and other resources associated with VLU care. The payer perspective 
was taken in the analysis and sensitivity analyses were performed to assess 
model uncertainty. RESULTS: SIS was the economically dominant therapy 
compared to FKSS and FSS with a comparative effectiveness ratio of $215 per 
ulcer-free week versus $367 and $409, respectively. Relative to SIS, the 
incremental cost-effectiveness ratio (ICER) for FKSS was $1609 while the ICER for 
FSS was $1132. SIS remained the least costly alternative per ulcer-free week 
across all sensitivity analyses. CONCLUSIONS: When cellular and/or tissue-
derived products are needed for chronic VLU therapy our results indicate that SIS 
is the most cost-effective choice between the three commercially available 
alternatives analyzed.  
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COST-EFFECTIVENESS OF DEXAMETHASONE INTRAVITREAL IMPLANT IN THE 
TREATMENT OF MACULAR EDEMA (ME) FOLLOWING CENTRAL RETINAL VEIN 
OCCLUSION (CRVO)  
Vicente C1, Koster B2, Zilbershtein R1, Piwko C1 
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OBJECTIVES: This pharmacoeconomic study evaluates the cost-effectiveness of 
OZURDEX™ (dexamethasone intravitreal implant) compared to observation 
(primary intervention at the time of model development) in management of 
patients with ME following CRVO, from a Canadian public payer and societal 
perspective. METHODS: A Markov model was developed to estimate lifetime 
outcomes and costs for patients with ME and vision loss following CRVO, 
receiving either OZURDEXTM implant or observation. The model consists of six 
heath states based on Best Corrected Visual Acuity (BCVA) and one absorbing 
(Death) state. The model was developed using GENEVA trial results with a 
systematic review for extrapolation of clinical data beyond the trial period. The 
model incorporated direct medical costs of managing patients with CRVO, 
treatment, drug related adverse events and vision loss; a societal perspective 
was examined as well. Utilities were derived from the published literature based 
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on the Visual Function Questionnaire – Utility Index and subsequent mapping to 
BCVA. Both costs (2012 Canadian dollars) and outcomes were discounted (5%). A 
Canadian panel of clinical experts in the treatment of CRVO validated the model 
structure and resource utilization. One-way and probabilistic sensitivity analyses 
(PSAs), were performed to test the robustness of the model to variations in key 
inputs. RESULTS: The resulting incremental cost-utility analysis (ICUR) was 
$21,568 and $14,103 from the public payer and societal perspective, respectively, 
for OZURDEXTM versus observation. Results of the one-way and multivariate 
analysis suggest that the results were robust. Throughout the 1,000 iterations  
of the PSA the ICUR consistently fell below a willingness-to-pay threshold of 
$50,000/QALY gained. Although robust, the model was most sensitive to age  
of entry and the utilities used for both the best-seeing eye and worst-seeing  
eye. CONCLUSIONS: Based on a willingness-to-pay threshold of $50,000/QALY 
gained, OZURDEX™ is a cost-effective treatment for CRVO compared with 
observation.  
 




VALIDATION AND COMPARISON OF THE SF-6D AND EQ-5D IN CHINESE 
PATIENTS WITH MODERATE TO SEVERE PSORIASIS  
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OBJECTIVES: To validate and compare the psychometric properties of two 
generic preference-based HRQoL instruments, EuroQol (EQ-5D) and Short-Form 
6D (SF-6D) among psoriasis patients in China. METHODS: Validity of the EQ-5D 
and SF-6D was examined with the patients in conjunction with Dermatology Life 
Quality Index (DLQI). Responsiveness was tested using the effect size (ES), 
relative efficiency (RE) and receiver operating characteristic (ROC) curves. 
Agreement between EQ-5D and SF-6D was tested using intra-class correlation 
coefficient (ICC) and Bland-Altman plot. RESULTS: A total of 150 moderate to 
severe patients were included with 50% female, mean age of 43.87 and mean 
disease duration of 5.19 years. The mean utility scores (SD) were 0.64 (0.32) for 
EQ-5D and 0.72(0.12) for SF-6D. There were no serious floor effects for EQ-5D and 
SF-6D but large ceiling effects for EQ-5D existed. Validity was demonstrated by 
the moderate to strong correlation coefficients (range: 0.50-0.71, P<0.001) for six 
of the ten hypotheses in both instruments. Both of EQ-5D and SF-6D showed a 
well discriminative capacity similarly (ES=0.98-1.27, ES=0.99-1.26) between 
groups with different psoriasis specific health status. RE showed that SF-6D 
(6.00-39.00%) was more efficient than EQ-5D in three domains of DLQI  
(recreation, relationships and treatment). Conversely, SF-6D (−1.00 - −13.00%) was 
less efficient than EQ-5D in three domains of DLQI (symptoms and feelings, daily 
activities and work and studies). The areas under ROC of them all exceeded  
0.5 (0.71- 0.84, P<0.001). Poor agreement between them was observed with  
ICC (0.38, P<0.001) and Bland-Altman plot analysis. CONCLUSIONS: This  
study provides evidence that EQ-5D and SF-6D are valid and sensitive 
preference-based HRQoL instruments in Chinese patients with moderate to 
severe psoriasis. SF-6D may be a more effective tool with lower ceiling effect. 
Further study is needed to compare other properties, such as reliability and 
longitudinal response.  
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OBJECTIVES: To assess health utilities and examine factors affecting health utilities 
among patients with moderate to severe psoriasis in China. METHODS: Data were 
obtained from a cross-sectional HRQoL survey of psoriasis patients in 29 tertiary 
hospitals of 7 cities in China from June to July, 2012. Eligible patients were assessed 
with moderate to severe psoriasis by physicians and treated with prescriptions 
during the visit/hospitalization. Degree of moderate and severe was estimated by 
physicians based on definition of BSA score 3-10% and >10%. Participants 
completed HRQoL measures of EuroQol 5 domains (EQ-5D), Short Form 6 domains 
(SF-6D) and Dermatology Life Quality Index (DLQI). Socio-demographic and 
treatment satisfaction information were also collected from the participants. Mean 
scores were compared and stepwise multivariate linear regression was conducted 
to assess factors associated with health utilities. RESULTS: A total of 150 patients 
were included with 50% female, mean age of 43.87 years and mean disease duration 
of 5.19 years. About 22.67% patients reported having at least one comorbidity with 
anxiety/depression (14.00%) and related infection (10.00%) listed on the top. 36.67% 
patients expressed dissatisfaction with their current treatment. Mean EQ-5D,  
EQ-VAS, SF-6D and DLQI scores were 0.64, 63.23, 0.72 and 11.09, respectively, with 
significant difference between the severe and moderate group in all measures(0.50 
vs. 0.77, 58.12 vs. 67.48, 0.67 vs.0.75, 14.43 vs. 8.33, all p<0.001). Regression analysis 
indicated that health severity indicated by DLQI score was significantly associated 
with value scores of EQ-5D, EQ-VAS, SF-6D. Sleeplessness and living in Tier 1st city 
decreased EQ-5D and SF-6D scores and treatment dissatisfaction had the negative 
impact on EQ-VAS and SF-6D scores with statistic significant. CONCLUSIONS: 
Compared with moderate patients, patients with severe psoriasis have poorer 
health utilities. Increasing the patients’ satisfaction with their treatment and 
controlling insomnia may raise their health utilities effectively.  
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OBJECTIVES: Psoriasis (PsO) is a systemic, inflammatory disease manifesting in 
the skin and associated with psoriatic arthritis. The objective of this study was to 
describe and quantify patients’ disease experiences, including symptoms and 
impact on daily lives and function. METHODS: This observational study was 
conducted in patients with moderate-to-severe PsO across 8 US sites. Qualitative 
data were obtained through semi-structured face-to-face interviews, including 
open-ended questions and patients’ ranking of bothersome symptoms. 
Quantitative data were captured using a case report form addressing 
demographic and clinical characteristics and standard measures of disease 
severity. Each interview was transcribed and thematically coded; all mentions of 
symptoms and areas of life-impact were quantified. Qualitative (ATLAS.ti) and 
quantitative (SAS) software analysis tools were used. RESULTS: A total of 101 
patients participated. Mean age was 49 years (SD = 14), mean duration of disease 
was 19 years, and 54% were male. Patients averaged 15% of body surface area 
involved with PsO. Mean Psoriasis Area and Severity Index score was 8.7 (SD = 
8.0) and 46% of patients were receiving biologic therapy. The most frequent 
patient-reported symptoms were flaking/scaling (non-scalp areas) (90%), 
itching/scratching (88%), rash (75%), flaking/scaling (scalp area) (63%), skin pain 
(63%), skin bleeding (59%), and redness (58%). Most bothersome symptoms were 
itching/scratching, flaking/scaling (non-scalp areas), and skin pain. Nearly all 
patients reported an emotional (98%) and social (95%) life-impact. Other impacts 
included family (74% of patients), professional (69%), physical (52%), educational 
(23%), and sexual (21%). Positive and negative treatment-related experiences 
were reported. CONCLUSIONS: Results provide a detailed description of PsO 
symptoms and identify important targets for treatment based on the patient 
perspective. PsO has a significant multidimensional impact on patients’ lives. 
Recording patient interviews and coding the themes, symptoms, and impacts of 
PsO provide rich material for analysis of patients’ health-related quality of life.  
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PATIENT REPORTED OUTCOMES IN GLAUCOMA A SYSTEMATIC REVIEW  
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OBJECTIVES: Patient reported outcomes (PRO) are becoming useful tools for 
collecting and generating evidence for new medical products to show 
improvements in health-related quality of life (HRQoL). Glaucoma is a chronic 
disease with high importance for patient HRQoL. The objective of this study was 
to review, analyze, and understand trends in the PRO instruments used in 
patients with Glaucoma. METHODS: A systematic literature search for Glaucoma 
trials with PROs endpoints was undertaken for the databases Pubmed, Embase, 
Biosis, Google Scholar and Cochrane. Data was collected for the study size, 
interventions, year, PRO instrument and results for PROs. Analysis for conducted 
to identify trends in commonly used PRO instruments and categorize results as 
positive, neutral or negative. RESULTS: Thirty-one studies with a total of 9819 
patients were identified. In these studies there were eleven different PROs 
instruments were identified that were Glaucoma health perception index, 
Glaucoma quality of life questionnaire (Glau-QoL), Glaucoma utility index, 
Impact of vision impairment, Low vision quality of life questionnaire, National 
eye institute visual function index-19 items, National eye institute visual 
function index-51 items, Nursing home vision quality of life questionnaire, 
Quality of life and visual function questionnaire, Vision core module 1, and 
Vision quality of life index. The most commonly used instruments were Impact 
of vision impairment (used in 7 studies) and Low vision quality of life 
questionnaire (used in 4 studies). CONCLUSIONS: Patients with glaucoma have 
significant impairment in their QoL, hence collection of such data is important 
for new medical products. PRO instruments such as Impact of vision impairment 
and Low vision quality of life questionnaire have been commonly used to 
generate evidence to show which therapies improve patient QoL.  
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OBJECTIVES: To develop a conceptual framework of functional reading 
independence to support development of a patient-reported outcome (PRO) 
measure for patients with geographic atrophy (GA) from age-related macular 
degeneration. METHODS: The conceptual framework was developed based  
on a literature review, expert opinion and patient input. Patient input was 
gathered in a qualitative concept elicitation study with 23 GA patients, where 
functional reading independence emerged as the most relevant concept. A draft 
conceptual framework and PRO questionnaire (interviewer-administered) were 
developed. Cognitive interviews were then conducted with 17 additional  
GA patients to assess understanding, completeness and relevance of the concept 
